Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs

Excerpt:

“The 5 FDA-approved HER2-targeted agents have altered the natural course of HER2-positive breast cancer, explained Sara A. Hurvitz, MD, at the 2018 Miami Breast Cancer Conference (MBCC).

” ‘These therapies have altered the way patients can now live with this disease,’ said Hurvitz, noting that the stage is now set for the next wave of treatment breakthroughs.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Olaparib Breast Cancer Efficacy Highlighted in Added Analyses

Excerpt:

“Improvements in progression-free survival (PFS) with olaparib (Lynparza) over treatment of physician’s choice (TPC) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation (gBRCA1/2m), according to an exploratory analysis from the phase III OlympiAD trial presented at the 2018 Miami Breast Cancer Conference (MBCC).

“Although not powered to show statistical significance between the groups, in those with one metastatic site (n = 71) the median PFS with olaparib was 8.4 months compared with 4.2 months with TPC (HR, 0.62; 95% CI, 0.35-1.13). In patients with ≥2 metastatic sites (n = 231), the median PFS was 6.5 months with olaparib compared with 3.0 months for TPC, which crossed the barrier for statistical significance (HR, 0.59; 95% CI, 0.43-0.82).”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.